Kangenbei's (600572.SH) subsidiary Muskol Drops has obtained approval for a new indication clinical trial application.

Tencent Finance App News, Kangenbei (600572.SH) announced that its wholly-owned subsidiary Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. (referred to as "Inner Mongolia Kangenbei") recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the new indication of musk tonifying heart drops pills. The new indication applied for this time is heart failure with preserved ejection fraction (qi deficiency and blood stasis syndrome in traditional Chinese medicine), and the route of administration is oral.